ROCH.NEO ROCHE HOLDING AG CDR (CAD Hedged)
- Total assets
- -
- Expense ratio
- -
- Dividend yield
- -
- 1-year return
- -
- Holdings
- 1
- Since
- -
Fund data as reported by the issuer, updated Oct 30, 2026. Total assets are in the fund's base currency.
What does ROCH.NEO invest in?
The holdings of ROCHE HOLDING AG CDR (CAD Hedged) are not available yet.
ROCHE HOLDING AG CDR (CAD Hedged) performance
Sharpe ratio 0.00Return figures of ROCHE HOLDING AG CDR (CAD Hedged) are not available yet.
ROCH.NEO price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About ROCHE HOLDING AG CDR (CAD Hedged)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various dise…
Full fund profileROCHE HOLDING AG CDR (CAD Hedged) top holdings
The holdings of ROCHE HOLDING AG CDR (CAD Hedged) are not available yet.
ROCHE HOLDING AG CDR (CAD Hedged) fund profile
- Fund name
- ROCHE HOLDING AG CDR (CAD Hedged)
- Ticker
- ROCH.NEO
- Exchange
- NEO Exchange
- Issuer
- -
- Index tracked
- -
- Category
- -
- Inception date
- -
- Trading currency
- CAD
- Expense ratio
- -
About ROCHE HOLDING AG CDR (CAD Hedged)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.